Summary

Legend Biotech’s scientific founder, Dr. Frank Fan, has returned to the ASCO stage after nine years. This announcement stems from a new strategy aimed at addressing the manufacturing cost and production speed challenges of existing CAR‑T therapies. The high‑yield, gene‑editing‑free CAR‑T platform refers to a technology that enables large‑scale T‑cell production without genetic editing. This approach is expected to simplify the manufacturing process and substantially reduce costs. The new platform combines two key elements: high yield and gene‑editing‑free methodology. High yield means securing a large proportion of target cells during production, while gene‑editing‑free indicates the ability to generate effective cell therapies without nucleases such as CRISPR. Consequently, production time and quality variability can be reduced. The CAR‑T market is currently dominated by gene‑editing‑based products. However, these products face scalability challenges due to manufacturing complexity, high costs, and supply‑chain constraints. Legend Biotech’s gene‑editing‑free approach seeks to overcome these limitations and has the potential to broaden accessibility for a larger patient population. From the perspective of investors and researchers, a successful platform could reshape the overall CAR‑T market structure. For patients, lower treatment costs and expanded therapeutic options are anticipated. Nonetheless, because the technology validation and clinical data are still in early stages, careful observation is warranted.